However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

The global cancer vaccines market, valued at US$10.23 billion in 2023, is forecasted to grow at a robust CAGR of 8.6%, ...

Physicians, nurse practitioners, or physician assistants prescribed medication to patients with OUD, while intervention ...

DelveInsight's Germ Cell Tumors Market Insights report includes a comprehensive understanding of current treatment practices, ...

Title: GOBLET platform study: Preliminary safety and tumor response results for the relapsed anal carcinoma cohort in patients treated with pelareorep and atezolizumab. Session Title: Poster Session C ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% ...

The global cervical dysplasia treatment market is poised for steady growth, with a projected valuation of US$ 846.2 million ...

Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.